How 335,000 Pharmacists Could Close the 86,000 Doctor Shortage by 2036

The U.S. faces a physician shortage of up to 86,000 by 2036, according to the AAMC's 2024 workforce projections. Meanwhile, 335,100 pharmacists already work in U.S. communities, most of them within five miles of where Americans live. A growing wave of state laws is rewriting what those pharmacists can legally do, and the implications for healthcare hiring and career pivots are bigger than most job seekers realize.

Why is the doctor shortage projected to hit 86,000 by 2036?

The AAMC's most recent projection puts the gap between 13,500 and 86,000 physicians within twelve years, with primary care alone short between 20,200 and 40,400 doctors and surgical specialties short another 10,100 to 19,900. The shortage is demand-driven, not just supply-driven. The U.S. population is expected to grow 8.4% by 2036, but the population aged 65 and older will grow 34.1%, and the 75-plus cohort will swell 54.7%. Older patients see physicians more often, take more prescriptions, and manage more chronic conditions per visit. Residency slots have not kept pace with medical school graduate volume, medical school capacity is constrained by federal Medicare funding caps on residency positions, and physicians are retiring earlier than projected after the pandemic. Burnout surveys from the AMA and Mayo Clinic continue to show roughly half of practicing physicians reporting symptoms, accelerating the retirement curve further. Even optimistic scenarios in the AAMC model still leave a multi-thousand-doctor gap, and the HRSA workforce dashboard projects shortages concentrated in rural counties, primary care, and psychiatry. Patching that hole requires more than producing new MDs, which is part of why nursing school enrollment is climbing and why ambulatory pharmacy roles are quietly multiplying.

The geographic distribution of the shortage matters as much as the headline number. The AAMC and HRSA both project that rural counties, the South, and the Mountain West will absorb a disproportionate share of unfilled physician demand, with Health Professional Shortage Area designations already covering more than 7,000 primary care zones across the country. Hospital systems in those regions are already pre-positioning by hiring nurse practitioners, physician assistants, and clinically expanded pharmacists at a faster clip than they are recruiting new MDs, simply because the licensing pipeline for advanced-practice clinicians is shorter and the labor pool is deeper. Job seekers tracking healthcare hiring should treat the 86,000 figure less as a forecast and more as a hiring forecast for everyone adjacent to the physician role, including pharmacy.

How many pharmacists are in the United States right now?

Roughly 335,100 pharmacists were employed across the country in 2024, per the BLS Occupational Outlook Handbook. That is nearly four pharmacists for every primary care doctor the AAMC says the country will be short. Pharmacists earn a median annual wage of $137,480, the BLS reports, with the top 10% earning more than $172,040 and the bottom 10% still earning above $86,930. Employment is projected to grow 5% between 2024 and 2034, faster than the average for all occupations, with 14,200 openings expected each year. The supply is not the bottleneck. The legal framework that defines what a pharmacist can do without a physician co-signature is. And in 2025 and 2026, that framework is changing in nearly every state, alongside other shifts in healthcare job growth. Geographic distribution also matters here: pharmacies operate in counties that have no primary care physician at all, and roughly 90% of Americans live within five miles of a community pharmacy, a footprint no other prescribing profession can match.

The pharmacist workforce is also younger and more diverse than the physician workforce, which has implications for how quickly the labor pool can flex. About 63% of pharmacists are women, according to BLS demographic data, and the average age of a practicing pharmacist sits in the early forties, well below the early-to-mid-fifties average for physicians. That demographic profile means fewer near-term retirements relative to physicians, more practitioners with another fifteen to twenty productive years in the workforce, and a faster runway for scope expansion to translate into actual delivered care. Health systems building out ambulatory pharmacy teams are also reporting shorter time-to-fill for clinical pharmacist roles than for physician roles in the same specialties, a quiet operational advantage when systems are competing for primary care capacity.

What can pharmacists legally do that doctors usually do?

The scope has widened dramatically over the past decade. Every U.S. state now allows collaborative practice agreements, which let a pharmacist initiate, adjust, or discontinue medications under a written protocol with a prescribing physician. Under those agreements, pharmacists routinely manage hypertension, diabetes, cholesterol, anticoagulation, asthma, and depression. Studies cited by the CDC show pharmacist-led disease management improves blood pressure and HbA1c control compared with physician care alone, with documented reductions in hospital readmissions for heart failure and COPD patients. In California, Certified Advanced Practice Pharmacists can test and treat CLIA-waived conditions like flu and strep, furnish hormonal contraception, HIV PrEP and PEP, and Paxlovid directly to patients without a physician visit. Oregon and a growing list of other states reimburse pharmacists for testing, prescribing, and dispensing SARS-CoV-2 treatment. Vaccinations, naloxone distribution, smoking cessation counseling, and travel-medicine consultations are now standard pharmacy services in most states. The legal toolkit is no longer just fill-the-prescription. Pharmacists who pivot into ambulatory care, managed care, or specialty consulting roles are reshaping their own career path mid-stream.

The reimbursement side is catching up too, which is what turns a legal scope change into actual hiring. Most state Medicaid programs now pay pharmacists for at least some clinical services delivered under collaborative practice, and a growing list of commercial insurers are following suit for chronic-disease management, immunizations, and test-and-treat encounters. Provider status legislation has been a slow grind at the federal level, but state-level victories have created enough payment plumbing for hospital outpatient departments and Federally Qualified Health Centers to staff ambulatory pharmacist roles as a recurring revenue line rather than a loss leader. That shift is already showing up in job postings, where titles like Clinical Pharmacist, Ambulatory Care Pharmacist, and Population Health Pharmacist have multiplied across major health-system career sites over the past eighteen months. The work is no longer hypothetical; it is staffed, billed, and measured.

Which states are leading the scope-of-practice expansion?

Activity is everywhere. In 2025, 244 scope-of-practice and payment bills for pharmacists were introduced across 49 states. Washington's Department of Health accepted a sunrise review of House Bill 2116, which would let pharmacists prescribe independently under a standard-of-care model rather than through collaborative drug therapy agreements. Oregon temporarily authorizes test-and-treat through June 2026 with mandated reimbursement from state health benefit plans. California's Advanced Practice Pharmacist credential is now a decade old and continues to expand its formulary. Idaho, Montana, and Colorado have moved further by allowing pharmacists to prescribe for a broader set of acute conditions without a prior physician relationship, and several Midwestern states are debating similar bills in their 2026 sessions. The pattern echoes how nurse practitioners gained full-practice authority state by state over the past twenty years. It tracks a broader healthcare workforce reshuffle alongside hospital consolidation and the rollout of Medicare's new AI payment model, which ties reimbursement to outcomes rather than visit volume and rewards systems that deploy pharmacists clinically.

The legislative momentum is bipartisan and tracks with provider-shortage geography more than with party control. Red states like Idaho and Tennessee have pushed independent prescribing authority alongside blue states like California and Oregon, and purple states like Pennsylvania and Michigan are debating their own scope expansions in current sessions. The North Carolina Association of Pharmacists, the Texas Pharmacy Association, and the Ohio Pharmacists Association are all running coordinated provider-status campaigns aimed at adding pharmacists to the list of recognized billing providers under state Medicaid programs. National associations are sharing model bill language across state houses, which is compressing the learning curve. The result is a faster legislative cycle than the multi-decade march nurse practitioners took, with each new state win making it easier for hospital systems to standardize ambulatory pharmacist roles across multi-state footprints rather than redesigning workflows market by market.

What does a pharmacist career path look like in 2026?

Becoming a pharmacist is an eight-year commitment: a four-year undergraduate foundation plus four years for the Doctor of Pharmacy degree, capped by the NAPLEX exam and state-specific MPJE licensure tests. After licensure, the career splits in several directions, and the higher-paying and faster-growing tracks are increasingly clinical rather than retail. Ambulatory care pharmacists run chronic-disease clinics inside health systems and Federally Qualified Health Centers. Managed care pharmacists work for insurers, PBMs, and accountable care organizations designing formularies and quality programs. Specialty pharmacists handle oncology, HIV, and rare-disease therapies that often exceed $100,000 per year per patient, and they sit at the center of payer negotiations and patient coordination. Pharmacist informaticists sit between IT and clinical teams in hospitals, similar to how tech-adjacent skill paths are reshaping other knowledge-work careers. Residency-trained PharmDs typically out-earn retail counterparts within five years, and the demand for clinically expanded pharmacists is climbing as the doctor gap widens, mirroring the broader labor market signals showing where employer hiring is concentrated. Mid-career pivots into pharmacy informatics, regulatory affairs, or pharmacovigilance are increasingly common, and they follow the same career-pivot logic playing out across other licensed professions where automation is reshaping the bottom of the job ladder but expanding the top.

Compensation in the clinical tracks is starting to reflect the demand curve. Hospital and health-system ambulatory pharmacists with residency training routinely clear $135,000 to $160,000 in the first few years out of training, and specialty pharmacists in oncology or transplant can reach $170,000 to $200,000 with experience in major metro markets. Sign-on bonuses for residency-trained PharmDs in critical-access hospitals and rural health systems have climbed into the $20,000 to $40,000 range over the past two years as systems compete for clinically expanded talent. Pharmacy informatics, regulatory affairs, and pharmacovigilance roles inside biotech and managed-care organizations frequently cross $180,000 in total compensation, and remote-friendly arrangements have become more common for these positions than they were before 2020. For students weighing the eight-year commitment against shorter clinical pathways, the gap between the median retail-pharmacy salary and the median clinical-pharmacy salary has widened enough that residency match rates have rebounded after a brief mid-2020s dip, a signal that the market is pulling new graduates toward the higher-value side of the profession.

How does pharmacist-led care change job seekers' access to healthcare?

For workers without a primary care doctor, which a 2024 Kaiser Family Foundation survey put at roughly one in four U.S. adults, the pharmacy counter is becoming the front door. Test-and-treat programs let a patient walk into a participating pharmacy with flu symptoms, receive a rapid test, and walk out with a prescription in under thirty minutes. Hormonal contraception, smoking cessation counseling, naloxone, immunizations, and travel medications are all available without a prior physician visit in most states. For workers on hourly schedules who cannot easily take a half-day off for an appointment, this is a material change in healthcare access, and a quiet driver behind why workers are reconsidering their employment situation. For employers, expanded pharmacist services reduce avoidable urgent care visits and downstream claim costs, which is why a growing list of large self-insured employers now contract directly with pharmacy networks for chronic-disease management and biometric screenings. The job market implications are not subtle: more pharmacist hiring at health systems, more ambulatory care roles, more clinical pharmacy informatics openings, and a rising premium on PharmDs who can document outcomes, a shift that fits the same workforce pattern reflected in the March 2026 JOLTS report. For job seekers thinking about how to position a healthcare career, the pharmacist track is becoming one of the clearest examples of a regulated profession expanding rather than contracting under demographic pressure.

The downstream effect on labor mobility is also real. When workers can walk into a pharmacy for blood-pressure management, chronic refills, or a strep test, the friction of switching jobs, relocating, or going freelance drops. As pharmacist-led services expand cash-pay and insurance-billed encounters, the bargaining position of workers who want flexibility or contract work strengthens at the margin. That dynamic helps explain why healthcare and pharmacy hiring keep showing up as one of the most resilient categories in monthly BLS releases, and why the demand signal for clinical pharmacists is no longer subtle.

People Also Asked

Q: Can a pharmacist actually replace a primary care doctor?

A: Not entirely. Pharmacists cannot perform invasive procedures, order imaging beyond limited point-of-care tests, or manage complex undifferentiated diagnoses. What they can do under collaborative practice agreements and advanced practice credentials is take over the medication-management portion of chronic disease care, run test-and-treat for common acute conditions, and triage patients into the rest of the system. In primary care shortage areas, that load-shift can free physicians to focus on cases that genuinely require an MD, especially in rural counties where the gap is widest.

Q: Is becoming a pharmacist still worth the time and tuition in 2026?

A: The math has shifted but remains attractive in the right tracks. Retail pharmacy has been hit by chain consolidation and store closures, while hospital and clinical pharmacy jobs have boomed. PharmDs who pursue a one- or two-year residency in ambulatory care, critical care, or specialty pharmacy are commanding higher salaries and broader job options than retail-only counterparts. The eight-year time commitment is real, and tuition averages over $200,000 at private programs, so the calculation depends on track, geography, and willingness to relocate for residency.

Q: Will AI replace pharmacists?

A: AI is already reshaping pharmacy workflows in dispensing, drug interaction checking, and adherence monitoring. What it has not replaced is the clinical judgment required to manage patients with multiple chronic conditions and competing medications. Pharmacists who layer AI fluency on top of their clinical training tend to gain leverage rather than lose it, the same pattern showing up across other licensed professions navigating automation, and the AAMC's projected doctor shortage only widens the runway for clinically expanded pharmacist roles.

Ready to level up? Use Metaintro to plan your next move with AI-driven career intelligence.